Skip to content

Study · Randomized controlled trial · n = 36 · 2014

3 results

Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder.

Dodhia S, Hosanagar A, Fitzgerald DA, Labuschagne I, Wood AG, Nathan PJ, Phan KL

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology5 Mar 2014Cited by 167 (Europe PMC)

PMID24594871 (opens in a new tab)PMCIDPMC4104324 (opens in a new tab)DOI10.1038/npp.2014.53 (opens in a new tab)PepBankPUB-24594871
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In adults with generalized social anxiety disorder, oxytocin reversed the reduced amygdala-frontal connectivity seen relative to healthy controls on placebo.

    In plain wordsIn adults with social anxiety disorder, oxytocin brought low amygdala-frontal connectivity back toward the level seen in healthy people.

    Peptide
    Oxytocin
    Outcome
    IncreaseAmygdala-frontal connectivity relative to healthy controls
    Study

    n = 36

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24 IU (40.32 μg) · intranasalAs given in this study (human).

    Source sentences

    Summary
    reversed (ie, 'normalized') the reduced amygdala-frontal connectivity observed relative to HCs evident on PBO.
    1 context sentence
    Summary · context
    In a randomized, double-blind, cross-over design, 18 GSAD and 18 HC participants received intranasal OXT (24 IU or 40.32 μg) or placebo (PBO) before resting-state functional magnetic resonance imaging.
  2. 02HumanRandomized controlled trialMechanism

    In adults with generalized social anxiety disorder, intranasal oxytocin increased resting-state connectivity of the left and right amygdala with rostral anterior cingulate cortex and medial prefrontal cortex versus placebo.

    In plain wordsIn adults with social anxiety disorder, oxytocin spray raised connectivity between the amygdala and front brain areas more than placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseAmygdala-frontal resting-state connectivity
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    24 IU (40.32 μg) · intranasalAs given in this study (human).

    Source sentences

    Summary
    OXT enhanced rsFC of the left and right amygdala with rostral anterior cingulate cortex (ACC)/medial prefrontal cortex (mPFC)
    1 context sentence
    Summary · context
    In a randomized, double-blind, cross-over design, 18 GSAD and 18 HC participants received intranasal OXT (24 IU or 40.32 μg) or placebo (PBO) before resting-state functional magnetic resonance imaging.
  3. 03HumanRandomized controlled trialMechanism

    In adults with generalized social anxiety disorder, higher social anxiety correlated with a greater oxytocin-induced enhancement of amygdala-frontal connectivity.

    In plain wordsIn adults with social anxiety disorder, people with more anxiety showed a bigger oxytocin-linked rise in amygdala-frontal connectivity.

    Peptide
    Oxytocin
    Outcome
    Not applicableAssociation of social anxiety severity with oxytocin-induced connectivity change
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    24 IU (40.32 μg) · intranasalAs given in this study (human).

    Source sentences

    Summary
    higher social anxiety also correlated with greater enhancement in amygdala-frontal connectivity induced by OXT.
    1 context sentence
    Summary · context
    In a randomized, double-blind, cross-over design, 18 GSAD and 18 HC participants received intranasal OXT (24 IU or 40.32 μg) or placebo (PBO) before resting-state functional magnetic resonance imaging.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.